ORTHOX HOLDINGS LIMITED

• ⚠

  Material uncertainty over going concern

  Note 1.3 in the financial statements indicates that due to adverse results on recent clinical trials, the company's ability to continue as a going concern is reliant upon ongoing investigation and cost restructuring. These conditions indicate a material uncertainty exists that may cast significant doubt on the company's ability to continue as a going concern.

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  —

  Not reported

• Cash

  +126,190.6%

  £277 → £349,825

• Net assets

  -109.3%

  -£506,245 → -£1,059,416

• Employees

  -70%

  10 → 3

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102 §1A

Reporting scope

Consolidated group

Abridged

Yes — abridged accounts (limited disclosure)

Auditor

Alison Richardson Richardsons

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“Note 1.3 in the financial statements indicates that due to adverse results on recent clinical trials, the company's ability to continue as a going concern is reliant upon ongoing investigation and cost restructuring. These conditions indicate a material uncertainty exists that may cast significant doubt on the company's ability to continue as a going concern.”

Group structure

1. ORTHOX HOLDINGS LIMITED · parent
   1. Orthox Limited 100% · Oxfordshire

Significant events

• “Adverse clinical results on the FFLEX trial in 2023, leading to cost rationalisation and reduced company expenditure.”
• “Licensing of IP related to cartilage repair material from Imperial College London and KTP grant from Innovate UK.”
• “Wellcome Trust provided letter of comfort not to call in their loan for at least the next 3 years.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

6

last 12 months

Capital events

2

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.